Teva Pharmaceutical Industries ROE 2010-2024 | TEVA

Current and historical return on equity (ROE) values for Teva Pharmaceutical Industries (TEVA) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Teva Pharmaceutical Industries ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2024-06-30 $-0.45B $6.56B -6.08%
2024-03-31 $-0.48B $7.54B -6.19%
2023-12-31 $-0.56B $8.13B -7.00%
2023-09-30 $-2.33B $7.51B -28.70%
2023-06-30 $-2.35B $7.71B -27.31%
2023-03-31 $-1.71B $8.61B -18.72%
2022-12-31 $-2.45B $8.60B -25.61%
2022-09-30 $-1.29B $9.52B -12.63%
2022-06-30 $-1.05B $9.83B -9.85%
2022-03-31 $-0.62B $10.26B -5.56%
2021-12-31 $0.42B $11.24B 3.71%
2021-09-30 $0.73B $11.45B 6.48%
2021-06-30 $-3.92B $11.31B -35.64%
2021-03-31 $-3.98B $10.98B -33.57%
2020-12-31 $-3.99B $11.06B -31.25%
2020-09-30 $-4.03B $10.59B -29.28%
2020-06-30 $0.00B $14.82B 0.03%
2020-03-31 $-0.83B $14.59B -5.52%
2019-12-31 $-1.00B $15.06B -6.54%
2019-09-30 $-4.05B $14.93B -26.20%
2019-06-30 $-4.01B $15.25B -24.28%
2019-03-31 $-3.56B $15.82B -20.30%
2018-12-31 $-2.40B $15.79B -12.90%
2018-09-30 $-11.06B $19.13B -57.19%
2018-06-30 $-10.26B $19.37B -46.35%
2018-03-31 $-16.05B $20.10B -65.01%
2017-12-31 $-16.53B $18.75B -57.78%
2017-09-30 $-5.96B $30.30B -18.26%
2017-06-30 $-6.15B $29.61B -17.89%
2017-03-31 $0.08B $35.75B 0.22%
2016-12-31 $0.07B $34.99B 0.20%
2016-09-30 $1.59B $37.03B 4.91%
2016-06-30 $1.35B $32.02B 4.66%
2016-03-31 $1.70B $30.59B 6.37%
2015-12-31 $1.57B $29.93B 6.38%
2015-09-30 $1.78B $22.90B 7.72%
2015-06-30 $2.55B $23.09B 10.98%
2015-03-31 $2.76B $22.68B 11.82%
2014-12-31 $3.06B $23.36B 13.05%
2014-09-30 $2.75B $23.67B 11.83%
2014-06-30 $2.58B $23.59B 11.27%
2014-03-31 $1.38B $23.03B 6.17%
2013-12-31 $1.27B $22.64B 5.67%
2013-09-30 $1.21B $22.39B 5.39%
2013-06-30 $0.42B $21.61B 1.85%
2013-03-31 $1.73B $22.81B 7.57%
2012-12-31 $1.96B $22.87B 8.53%
2012-09-30 $2.15B $23.07B 9.39%
2012-06-30 $3.14B $22.89B 13.76%
2012-03-31 $2.86B $23.20B 12.39%
2011-12-31 $2.76B $22.34B 11.97%
2011-09-30 $3.02B $22.94B 13.17%
2011-06-30 $3.16B $23.75B 13.94%
2011-03-31 $3.38B $23.13B 15.68%
2010-12-31 $3.33B $22.00B 16.10%
2010-09-30 $2.94B $21.71B 14.69%
2010-06-30 $2.54B $19.36B 13.08%
2010-03-31 $2.26B $19.68B 11.89%
2009-12-31 $2.00B $19.26B 11.03%
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $20.902B $15.846B
Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm.
Stock Name Country Market Cap PE Ratio
Dr Reddy's Laboratories (RDY) India $12.399B 18.57
BridgeBio Pharma (BBIO) United States $4.791B 0.00
Bausch Health Cos (BHC) Canada $3.597B 2.61
Amphastar Pharmaceuticals (AMPH) United States $2.469B 13.82
Supernus Pharmaceuticals (SUPN) United States $1.872B 377.44
Taysha Gene Therapies (TSHA) United States $0.314B 51.00
Personalis (PSNL) United States $0.270B 0.00
Assembly Biosciences (ASMB) United States $0.107B 0.00
Acasti Pharma (GRCE) Canada $0.031B 0.00
Sol-Gel Technologies (SLGL) Israel $0.014B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00